News Release

August 30, 2011

Contact: Steffen Grimminger Phone: +1-978-715-1220 Email: steffen.grimminger@merckgroup.com

EMD Millipore Strengthens Bioscience Business by acquiring Amnis Corporation

• Acquisition adds world-class cell imaging capabilities in fast growing flow cytometry market

August 30, 2011, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA* of Germany, today announced it has agreed to acquire Seattle-based Amnis Corporation. Amnis designs, manufactures and markets high speed cell imaging instrumentation. The technology is used in flow cytometry applications in academic, biotech and pharmaceutical cell analysis and research. Amnis has 40 employees and generated sales of 14 million USD in 2010. The transaction is subject to regulatory approvals and closing is expected to take place in the fourth quarter of 2011. Terms of the transaction were not disclosed.

“Amnis’ technology will put EMD Millipore at the forefront of cell analysis by providing us access to break-through, combined imaging flow cytometry, addressing several unmet needs in the field of cell analysis and systems biology,” said Jonathan DiVincenzo, head of EMD Millipore’s Bioscience business unit. “Today there are no comparable alternatives that enable our customers to combine flow cytometry and image analysis in one integrated solution. With this acquisition, EMD Millipore becomes the only provider of this technology.”

The acquisition significantly enhances EMD Millipore’s product portfolio in the attractive growth segment of flow cytometry. Specifically, the business will complement EMD Millipore’s existing Guava product range, a business EMD Millipore acquired in 2009. “With Amnis we acquire a business with a talented workforce, a strong intellectual property position, and unique know-how which will position us to create tremendous value for our customer’s research outcomes in the flow cytometry workflow” added DiVincenzo.

David A. Basiji, co-founder and CEO of Amnis comments, “The combination of Amnis with EMD Millipore will greatly accelerate development of novel applications in imaging flow cytometry, enhance our customer support, and accelerate product development.” William E. Ortyn, Amnis’ co-founder and President adds, “We look forward to becoming a member of Merck KGaA of Germany and the new possibilities to pursue compelling opportunities in both the life science research and clinical markets.”

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of USD 2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

About Merck
Merck is a global pharmaceutical and chemical company with total revenues of EUR 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany